Q1: 2026-05-05 Earnings Summary
EPS of -$1.54 misses by $0.08
|
Revenue of
$136.00M
(-2.36% Y/Y)
misses by $19.87M
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call May 5, 2026 5:00 PM EDT
Company Participants
Joshua Higa - Director of Investor Relations & Corporate Communications
Emil Kakkis - Founder, President, CEO & Director
Erik Harris - Executive VP & Chief Commercial Officer
Howard Horn - Executive VP of Corporate Strategy & CFO
Eric Crombez - Chief Medical Officer & Executive VP
Conference Call Participants
Joseph Schwartz - Leerink Partners LLC, Research Division
Maurice Raycroft - Jefferies LLC, Research Division
Joyce Chang Robbins - JPMorgan Chase & Co, Research Division
Eliana Merle - Barclays Bank PLC, Research Division
Steven Ionov - TD Cowen, Research Division
Salveen Richter - Goldman Sachs Group, Inc., Research Division
Kristen Kluska - Cantor Fitzgerald & Co., Research Division
Selena Zhang - Morgan Stanley, Research Division
Jack Allen - Robert W. Baird & Co. Incorporated, Research Division
Benjamin Burnett - Wells Fargo Securities, LLC, Research Division
Yigal Nochomovitz - Citigroup Inc., Research Division
Luca Issi - RBC Capital Markets, Research Division
Amit Dayal - H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good afternoon, and welcome to Ultragenyx First Quarter 2026 Financial Results Conference Call. [Operator Instructions]
It is now my pleasure to introduce your host, Joshua Higa, Vice President of Investor Relations.
Joshua Higa
Director of Investor Relations & Corporate Communications
Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; Howard Horn, Chief Financial Officer; and Eric Crombez, Chief Medical Officer.
I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.
I'll now turn the
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。